New Approach to Islet Transplantation Shows Promise Outside the Liver
Researchers tested a biodegradable implant placed under the skin as a site for transplanting insulin-producing cells. Early results suggest this approach is safe and may help some people with Type 1 diabetes produce insulin again.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Scientists used a special biodegradable material called Novosorb BTM to create a vascularized (blood-vessel-rich) pocket under the skin for islet cell transplants
- In a small pilot study of three kidney transplant recipients, one person showed signs of insulin production three months after the procedure
- All three participants saw improvements in blood sugar control (HbA1c) and reduced insulin requirements over 12 months
- One participant maintained graft function and continued producing detectable insulin more than 3.5 years after the transplant
- This extrahepatic (outside-the-liver) transplant site is retrievable, offering a potentially safer alternative to traditional liver-based approaches
A New Location for Insulin-Producing Cell Transplants
For decades, researchers have explored ways to restore insulin production in people with Type 1 diabetes through islet cell transplantation. Traditionally, these cells are placed in the liver. Now, scientists are testing whether transplanting islet cells under the skin—using a specially designed biodegradable implant—could work just as well, or even better.
The implant in question is made from a polyurethane material called Novosorb BTM. It creates a pre-vascularized pocket under the skin, meaning blood vessels naturally develop within it before the islet cells are transplanted. This vascularization is crucial because transplanted cells need a good blood supply to survive and function.
What the Research Showed
Researchers first tested the approach in immunosuppressed pigs, implanting human stem cell-derived islets (HSCI) into the Novosorb BTM pocket. The islet clusters survived and remained present throughout the 28-day observation period.
The team then moved to a human pilot study called INCEPTR, involving three adults with Type 1 diabetes who were also kidney transplant recipients. All three underwent outpatient surgery to place the Novosorb BTM implant under the skin, followed by transplantation of human islet cells.
At three months, one of the three participants showed detectable C-peptide in the blood—a marker that the transplanted islet cells were producing insulin. While this represents modest success in a very small group, the finding suggests the approach is feasible.
Improvements in Blood Sugar Control
Beyond the primary measure of C-peptide detection, all three participants showed clinically meaningful improvements over the 12-month follow-up. Their HbA1c levels (a measure of average blood sugar over three months) dropped by 0.6% to 1.3%, indicating better overall glucose control.
Additionally, all three participants needed less insulin than they did before the transplant. Reductions in daily insulin requirements ranged from 7% to 49%, a substantial decrease for some individuals. These improvements in insulin dependency suggest the transplanted cells were contributing to glucose regulation, even when C-peptide was not consistently detected.
Long-Term Durability and Safety Considerations
The most encouraging finding came from one participant who maintained detectable serum and urinary C-peptide and demonstrated mixed-meal responsiveness—the ability to produce insulin in response to eating—more than 3.5 years after transplantation. This long-term function suggests the islet cells can survive and work in this subcutaneous location over extended periods.
An important advantage of placing the implant under the skin rather than in the liver is that it is retrievable if complications arise. This accessibility could make the procedure safer and more practical for future applications. The researchers note that the Novosorb BTM site safely supported human islet survival and function, albeit at a modest level, in this extrahepatic location, potentially opening the door to new cellular therapy platforms for Type 1 diabetes.
What This Means for the Future
This pilot study represents an early-stage exploration of a novel transplantation site and technique. The results are promising but preliminary, based on a small number of participants. The modest level of insulin production observed and the variable outcomes among the three participants highlight that more research is needed to optimize the approach.
If further studies confirm these findings, an implant-based, subcutaneous transplant strategy could offer people with Type 1 diabetes another option for restoring endogenous (the body's own) insulin production—with the added advantage of a removable, retrievable site. However, like all islet transplantation approaches, this would still require immunosuppressive medication to prevent the body from rejecting the foreign cells.
Evidence label
Source: Cell transplantation. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Our own writing on the same ground.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
- OriginalType 1 diabetes research watch: recent papers and DOI records worth sortingA daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCure & AdvancementsGene-Edited Islets Show Promise, But Long-Term Questions RemainPubMed indexed literature
- Research summaryCure & AdvancementsHow Islet Size Shapes Cell Composition: What Scientists Found in Healthy PancreasesPubMed indexed literature
- Research summaryCure & AdvancementsStem Cell-Derived Islets: A New Research Path Toward Restoring Insulin ProductionPubMed indexed literature
- Research summaryCure & AdvancementsBerberine Shows Promise for Pancreatic Cell Recovery in Type 1 Diabetes ResearchPubMed indexed literature
- Research summaryCure & AdvancementsHow Gut Bacteria May Influence Type 1 Diabetes Risk Through Immune ControlPubMed indexed literature
- Research summaryCure & AdvancementsNew Blood Test May Help Identify Type 1 Diabetes EarlierPubMed indexed literature